T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Although immunotherapy has revolutionized the treatment of many cancers, ovarian cancer
patients have not yet benefitted from the advances.
In two consecutive pilot trials at National Center for Cancer Immune Therapy (CCIT-DK), is
has been have shown that adoptive cell therapy (ACT) with TILs for patients with advanced
ovarian cancer (OC) is feasible and tolerable. In the most recent of these trials ACT was
combined with a CTLA-4 inhibitor, Ipilimumab and a PD1-inhibitor, Nivolumab. Only transient
clinical responses where observed.
Between 90-100 % of infused T-cells in our previous ovarian cancer ACT trial expressed LAG-3.
The interaction between LAG-3 on T-cells and MHC-II on tumor cells inhibits T-cell function.
In this study adding the LAG-3 antibody Relatlimab to the ACT-regimen described above may
therefore well unleash T-cell antitumor efficacy by blocking the known LAG-3-MHC-II
interaction.
With this study the aim is to demonstrate that adding the lag-3-inhibitor Relatlimab to the
above treatment regimen is feasible and tolerable. The study will elucidate whether the
combination Relatlimab-Nivolumab leads to objective responses and improves progression free
survival (PFS).